[PDF] Top 20 Cripto-1 as a novel therapeutic target for triple negative breast cancer

... among Cripto-1/Tdgf-1, Sox2, Bmp4, Cdh1 and miR-15/16, miR- 200 family, miR-99; which supports the observations in this detailed study of the JygMC(A) mouse model (Figure ... See full document

... The triple-negative breast cancer (TNBC) is a very aggressive tumor type often occurring in young women and is associated with a bad prognosis for the ...for breast cancer ... See full document

... levels. 1) The definition of TNBC was changed from the traditional categories of breast cancer ...effective therapeutic targets for TNBC in 2013 [12]; 7) The relationship between TNBC ... See full document

... EGFR highly overexpressed in majority of BL TN tumors [21]. BL TN tumors have seeking attention due to recognition as a distinct entity and due to poor prognosis that the diagnosis indicates. Some of the studies ... See full document

... and novel chemotherapeutic strategies can have limited success in the treatment of metastatic cancer, especially due to the development of multidrug resistance ...of triple-negative ... See full document

... Tumor-infiltrating lymphocytes (TILs), especially CD138-positive plasma cells and CD20-positive B lympho- cytes, were assessed according to recommendations of an international working group [12, 13]. The presence of ter- ... See full document

... for Triple Negative Breast Cancer ...a novel murine tumor ...combinatorial therapeutic approaches for stroma-directed tumor targeting using tumor models that have an appropriate ... See full document

... rabbit anti-human CXCR2 antibody (GR132442-8, Abcam, Cambridge, MA, USA) immunostaining. NANOG expres- sion was determined using mouse anti-human NANOG anti- body (0710165 G-1, Novus Biologicals, Littleton, CO, ... See full document

... Triple-negative breast carcinomas (TNBC) are characterized by particularly poor outcomes, and there are no established markers significantly associated with ...potential therapeutic targets ... See full document

... with cancer progression and thus serve as potential immunotherapeutic targets ...that breast cancer (BC) is a non-immunogenic disease with fewer immunogenic tumour antigens [10], so BC has not been ... See full document

... Triple-negative breast cancer (TNBC) is defined as a subtype of aggressive breast cancer, accounting for 10–20% of all breast cancer cases ...other breast ... See full document

... Breast cancer is currently the top ranked malig- nant tumor endangering the health of women, ...invasive breast cancer patients and 40,290 deaths were reported in the United States in ...of ... See full document

... of target-based therap- ies has improved the prognosis of cancer ...of novel targets is a challenging task for the medical on- cologist, and valuable prognostic markers might become potential ... See full document

... Sacituzumab govitecan is an antibody – drug conjugate in which SN-38 (an active metabolite of the topoisomerase I inhibitor, irinotecan) is coupled to a monoclonal antibody targeting anti-trophoblast cell-surface antigen ... See full document

... Figure 6. miR-4306 inhibits TNBC cell growth, lung metastasis, angiogenesis and lymphatic metastasis in vivo. (A-D) The mice were injected subcutaneously in their top backs with 1×106 cells in 0.1 mL. Growth of ... See full document

... More recently, studies have highlighted the role of metadherin (MTDH) in stimulating tumor progression, metastasis, and drug resistance in various cancers. MTDH is an oncogene that was originally identified as a gene in- ... See full document

... 73–485, 1–60, 1–72, 1–141, and 60–72) were used to indicate the binding domain of MZF-1 (upper ...acids 1–72 and 60–72) of MZF-1 in which the negatively charged aspartates in ... See full document

... normal breast tissues from each patient with lung metas- tasis to evaluate miRNA dysregulation in microarray ...normal breast tissues from patients with TNBC without any re- ... See full document

... serous cancer without germline BRCA1 or BRCA2 mutations, which has illustrated that olaparib is a promising therapeutic option for women with these aggressive ... See full document

... other therapeutic targets, such as αβ-crystallin, Sox2, embryonic transcription factor, osteopontin, phosphorylated glycoprotein, nestin and type 4 intermediate fi lament ...caveolin 1 and caveolin 2 as a ... See full document